Heron Therapeutics Executive Compensation Details Released
Ticker: HRTX · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 818033
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
TL;DR
Heron Therapeutics DEF 14A shows exec comp details for 2024, including equity awards for Quart & Collard.
AI Summary
Heron Therapeutics, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel such as Barry Quart and Craig Collard, with specific details on changes in fair value and vesting schedules for these awards.
Why It Matters
This filing provides transparency into how Heron Therapeutics compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but details on executive compensation can sometimes signal changes in company strategy or performance, impacting stock value.
Key Numbers
- 2024 — Fiscal Year End (The period for which executive compensation is detailed.)
- 20250430 — Filing Date (The date Heron Therapeutics filed this DEF 14A.)
Key Players & Entities
- HERON THERAPEUTICS, INC. (company) — Filer of the DEF 14A
- Barry Quart (person) — Executive mentioned in compensation details
- Craig Collard (person) — Executive mentioned in compensation details
- 4242 CAMPUS POINT COURT, SUITE 200 (location) — Company's business and mailing address
- SAN DIEGO, CA (location) — Company's business and mailing city and state
FAQ
What is the total compensation reported for Barry Quart for the fiscal year ending December 31, 2024?
The filing indicates that Barry Quart is listed as a "PeoMember" and details equity awards, but the total dollar amount for his compensation in 2024 is not explicitly stated in the provided snippet.
What specific types of equity awards were granted to Craig Collard in 2024?
The filing mentions "EqtyAwrdsInSummryCompstnTblForAplblYrMember" and "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" for Craig Collard, suggesting equity awards were granted and their fair value changed.
What was the change in fair value of equity awards for Heron Therapeutics in 2023?
The filing references "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" for Barry Quart in 2023, indicating a change in fair value for vested prior-year equity awards.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code for Heron Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When did Heron Therapeutics change its name from AP Pharma Inc?
Heron Therapeutics, Inc. changed its name from AP Pharma Inc on May 11, 2001.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 by Barry Quart regarding HERON THERAPEUTICS, INC. /DE/ (HRTX).